Almirall SA
OTC:LBTSF

Watchlist Manager
Almirall SA Logo
Almirall SA
OTC:LBTSF
Watchlist
Price: 15.47 USD Market Closed
Market Cap: $3.3B

Gross Margin

73.7%
Current
Declining
by 0.7%
vs 3-y average of 74.4%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
73.7%
=
Gross Profit
€1.2B
/
Revenue
€1.6B

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
73.7%
=
Gross Profit
$1.2B
/
Revenue
€1.6B

Peer Comparison

Country Company Market Cap Gross
Margin
ES
Almirall SA
MAD:ALM
2.7B EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
972.2B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.5B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.1B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.4B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
272.1B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.3B USD
Loading...
FR
Sanofi SA
PAR:SAN
93.8B EUR
Loading...

Market Distribution

Higher than 78% of companies in Spain
Percentile
78th
Based on 599 companies
78th percentile
73.7%
Low
-178.8% — 38.9%
Typical Range
38.9% — 65.1%
High
65.1% — 192.7%
Distribution Statistics
Spain
Min -178.8%
30th Percentile 38.9%
Median 52.5%
70th Percentile 65.1%
Max 192.7%

Almirall SA
Glance View

Market Cap
3.3B USD
Industry
Pharmaceuticals

Almirall SA, a venerable player in the pharmaceutical industry, has its roots deeply embedded in the Spanish landscape where it began its journey in 1943. With a commitment to innovation and a keen focus on dermatology, the company has carved out a significant niche for itself. Almirall's core strategy revolves around the development, manufacturing, and commercialization of its proprietary medications, particularly those targeting skin conditions such as psoriasis and atopic dermatitis. By investing heavily in research and development, Almirall ensures its pipeline remains robust with promising drug candidates and innovative therapies that can meet the unmet needs of dermatology patients. This focus gives them a strategic edge, allowing them to leverage their scientific expertise and deliver state-of-the-art solutions to the market. The financial health of Almirall thrives on a clear business model that involves both direct sales and strategic partnerships. Through collaborations with other pharmaceutical giants and dynamic distribution networks, the company expands its reach beyond Europe, tapping into the American and Asian markets as well. Licensing agreements and co-development partnerships are key to its financial strategy, effectively allowing Almirall to maximize its intellectual property while sharing risks and costs. This multi-pronged approach ensures a steady revenue stream from both its branded products and its generics division, which supplements the overall profitability and sustainability of the company. As Almirall continues to navigate the competitive landscape of the pharma industry, its resilience and adaptability underscore its enduring legacy.

LBTSF Intrinsic Value
16.06 USD
Undervaluation 4%
Intrinsic Value
Price
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
73.7%
=
Gross Profit
€1.2B
/
Revenue
€1.6B
What is Almirall SA's current Gross Margin?

The current Gross Margin for Almirall SA is 73.7%, which is below its 3-year median of 74.4%.

How has Gross Margin changed over time?

Over the last 3 years, Almirall SA’s Gross Margin has decreased from 74.5% to 73.7%. During this period, it reached a low of 72% on Mar 31, 2024 and a high of 78.9% on Dec 31, 2022.

Back to Top